This article is more than 5 years old. Information may no longer be current.

AKB-9778 improves underlying diabetic retinopathy in TIME-2 study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AKB-9778 alone or in combination with ranibizumab improved underlying diabetic retinopathy in eyes with and without diabetic macular edema in the TIME-2 phase 2a study, Aerpio Therapeutics announced in a press release.

Patients in the TIME-2 study were administered 15 mg of AKB-9778 alone, 15 mg of AKB-9778 in combination with 0.3 mg of Lucentis (ranibizumab, Genentech) or 0.3 mg of ranibizumab alone.

At 3 months, both AKB-9778 study groups had an improvement in underlying retinopathy according to pre-specified analysis by two or more steps on the diabetic retinopathy severity scale.

Rates of two-step improvement were 10% in the AKB-9778 monotherapy arm, 11.4% in the combination arm and 8.8% in the ranibizumab arm, the release said.

In addition, in 11.4% of patients who received AKB-9778, the fellow eye had a two-step or greater improvement compared with 4.2% of patients who received ranibizumab alone.

“Based on this progress, we are continuing our dialogue with advisors and global regulatory agencies to rapidly design and implement the follow-on studies in diabetic retinopathy,” Steve Pakola, MD, chief medical officer of Aerpio, said in the release.